Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy.

Janssen JA, Lamberts SW.

Clin Endocrinol (Oxf). 2000 Jan;52(1):1-9. Review.

PMID:
10651746
2.
3.

Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type 2 diabetes.

Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, Young RJ, White A, Gibson JM.

Diabetes. 2002 Aug;51(8):2629-36.

4.

Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF-binding proteins.

Feldmann B, Jehle PM, Mohan S, Lang GE, Lang GK, Brueckel J, Boehm BO.

Growth Horm IGF Res. 2000 Feb;10(1):53-9.

PMID:
10753593
5.

Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics.

Waldbillig RJ, Jones BE, Schoen TJ, Moshayedi P, Heidersbach S, Bitar MS, van Kuijk FJ, de Juan E, Kador P, Chader GJ.

Curr Eye Res. 1994 Jul;13(7):539-46.

PMID:
7523030
6.

Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus.

Akturk M, Arslan M, Altinova A, Ozdemir A, Ersoy R, Yetkin I, Ayvali E, Gonen S, Toruner F.

Growth Horm IGF Res. 2007 Jun;17(3):186-93. Epub 2007 Feb 27.

PMID:
17329141
7.

[Decreased serum level of free bioavailable IGF-I in patients with diabetic retinopathy].

Feldmann B, Lang GE, Arnavaz A, Jehle PM, Böhm BO, Lang GK.

Ophthalmologe. 1999 May;96(5):300-5. German.

PMID:
10414118
8.

The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients.

Frystyk J, Bek T, Flyvbjerg A, Skjaerbaek C, Ørskov H.

Diabet Med. 2003 Apr;20(4):269-76.

PMID:
12675639
9.

Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25).

López-Bermejo A, Khosravi J, Fernández-Real JM, Hwa V, Pratt KL, Casamitjana R, Garcia-Gil MM, Rosenfeld RG, Ricart W.

Diabetes. 2006 Aug;55(8):2333-9.

10.

Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria.

Wedrychowicz A, Dziatkowiak H, Nazim J, Sztefko K.

Horm Res. 2005;63(5):245-51. Epub 2005 May 24.

PMID:
15920342
11.

The insulin-like growth factor system and Type 1 diabetic retinopathy during pregnancy.

Loukovaara S, Immonen IJ, Koistinen R, Rutanen EM, Hiilesmaa V, Loukovaara M, Kaaja RJ.

J Diabetes Complications. 2005 Sep-Oct;19(5):297-304.

PMID:
16112506
13.

[IGFBP-1 and its protective role in the pathogenesis of microangiopathy in type 1 diabetes mellitus].

Krsek M, Prázný M, Skrha J, Justová V, Lacinová Z.

Cas Lek Cesk. 2001 Apr 26;140(8):234-7. Czech.

PMID:
11392040
14.

The IGF-I system and the renal and haemodynamic effects of losartan in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial.

Zandbergen AA, Lamberts SW, Baggen MG, Janssen JA, Boersma E, Bootsma AH.

Clin Endocrinol (Oxf). 2006 Feb;64(2):203-8.

PMID:
16430721
15.

Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus.

Wedrychowicz A, Dziatkowiak H, Sztefko K, Wedrychowicz A.

Exp Clin Endocrinol Diabetes. 2004 Sep;112(8):435-9.

PMID:
15372363
16.

IGF-I and diabetes in adolescence.

Dunger DB, Acerini CL.

Diabetes Metab. 1998 Apr;24(2):101-7. Review.

PMID:
9592633
17.
18.
19.

Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: friends or foes?

Orskov H.

Metabolism. 1996 Aug;45(8 Suppl 1):91-5. Review.

PMID:
8769394
20.

Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.

Mohamed-Ali V, Pinkney J.

Treat Endocrinol. 2002;1(6):399-410. Review.

PMID:
15832492

Supplemental Content

Support Center